| Market Capitalization (Millions $) |
164 |
| Shares
Outstanding (Millions) |
142 |
| Employees |
159 |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-101 |
| Cash Flow (TTM) (Millions $) |
-85 |
| Capital Exp. (TTM) (Millions $) |
5 |
Quantum Si Incorporated
We are a forward-thinking life sciences firm on a mission to democratize single-molecule analysis by giving researchers and physicians access to the proteome, or the collection of proteins expressed within a cell. We have developed a proprietary universal single molecule detection platform that leverages the semiconductor industry, and we are first applying our technology to field proteomics to enable Next Generation Protein Sequencing ("NGPS"), which is the ability to sequence proteins in a massively parallel fashion (rather than sequentially, one at a time). The development of Next Generation DNA Sequencing ("NGS") has altered genetics and our ability to investigate and cure cancer. We believe that the capacity to sequence proteins in a comparable manner has the potential to reveal considerable biological information through higher resolution and unbiased access to the protein sequence.
Our platform is designed to offer a rapid workflow including both sample preparation and sequencing. Our platform is comprised of the Carbon' automated sample preparation instrument, the Platinum' NGPS instrument, the Quantum-Si Cloud' software service, and reagent kits and chips for use with our instruments. We intend to follow a systematic, phased approach to successfully launch and commercialize our platform for research use only ('RUO') in 2022, and have initiated our early access limited release to enable key thought leaders early access to our platform in 2021. We believe we are the first company to successfully enable NGPS, thus digitizing a substantial proteomics opportunity, which allows for a massively parallel solution at the ultimate level of sensitivity ' single molecule detection.
There is an immense opportunity to better characterize and understand the full complexity of the proteome through improved understanding of proteoforms (different versions of proteins) and post-translational modifications which impact a protein's location and function within a cell. In general, the proteome has been relatively unexplored compared to the genome. Proteins are the functional units of life. Our DNA is a blueprint for 'what could happen,' whereas proteins tell us 'what is happening.' A protein is composed of one or more long chains of amino acids, the sequence of which determines its structure and function within a cell and is partly determined by the DNA sequence of the gene that encodes it. This versatile class of macromolecule is involved in virtually all cellular processes, including replicating and transcribing DNA as well as activating and inactivating signaling pathways, such as turning on the immune system in response to an infection. We believe that a broader, unbiased view of the proteome is foundational for accelerating biological insights and has vast utility in a number of end markets, including basic research and discovery, translational research, diagnostics and medical applications. While genomic research provides valuable information about the role of genes in health and disease, proteins are more prevalent than nucleic acids and more relevant to understanding the nuanced continuum between health and disease. Our platform has the potential to enable users to study the proteome in an unbiased and scalable way, similar to the manner in which NGS technologies transformed genomics analysis.
We believe that our platform will offer a differentiated end-to-end workflow solution in a rapidly evolving proteomics tools market. Within our initial focus market of proteomics, our workflow will be designed to provide users a seamless opportunity to gain key insights into the immediate state of biological pathways and cell state. Our platform aims to address many of the key challenges and bottlenecks of legacy proteomic solutions, such as mass spectrometry ('MS'), which are complicated and often limited by complex manual sample preparation workflows, high instrument costs both in terms of acquisition and ownership and complexity with data analysis, which together prevent broad adoption. We believe our platform, which is designed to streamline sample preparation, sequencing, and data analysis at a lower instrument cost than legacy proteomic solutions, could allow our platform to have wide utility across the study of the proteome. For example, our platform could be used for biomarker discovery and disease detection, pathway analysis, immune response, and vaccine development, among other applications.
We have designed and developed a hardware and software solution to provide a full end-to-end solution.
Collectively, we believe our products provide a comprehensive and flexible platform. Each piece of our platform is designed to address specific bottlenecks in common proteomic workflows, which we believe will appeal to a broad audience of end users. We believe that our universal unbiased single molecule detection platform will enable a proteomics solution at an affordable cost, and provide users the opportunity to perform proteomics studies at scale. Our end-to-end launch product consists of Carbon', Platinum', Quantum-Si Cloud' and consumables. We believe we are the first company to successfully enable NGPS, thus digitizing a substantial proteomics opportunity, for a scalable and massively parallel solution at the ultimate level of sensitivity ' single molecule.
Company Address: 29 Business Park Drive Branford 6405 CT
Company Phone Number: 688-7374 Stock Exchange / Ticker: 0 QSI
|
